These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 14760772)

  • 1. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
    Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
    World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
    Zong D; Zeng Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
    Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
    Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers as a diagnostic key for hilar cholangiocarcinoma.
    Juntermanns B; Radunz S; Heuer M; Hertel S; Reis H; Neuhaus JP; Vernadakis S; Trarbach T; Paul A; Kaiser GM
    Eur J Med Res; 2010 Aug; 15(8):357-61. PubMed ID: 20947473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
    Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
    Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
    Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
    Tang X; Zhang J; Chen Y; Lan Z; Wang C
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
    Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
    Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Björnsson E; Kilander A; Olsson R
    Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma.
    Watanabe H; Enjoji M; Nakashima M; Noguchi K; Kinukawa N; Sugimoto R; Kotoh K; Nakamuta M; Nawata H; Watanabe T
    J Hepatol; 2003 Oct; 39(4):559-63. PubMed ID: 12971966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
    Connor S; Bosonnet L; Alexakis N; Raraty M; Ghaneh P; Sutton R; Neoptolemos JP
    Dig Surg; 2005; 22(1-2):80-5. PubMed ID: 15849467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
    Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.